Introduction
I have started embarking on the uncharted journey to commercialise our groundbreaking quantum therapeutic technology for hard-to-treat-cancers and here are my initial thoughts on the journey. This arose from research conducted in our EPSRC Healthcare Technology Challenge Award aimed at developing new wireless electrochemical therapeutics in the School of Pharmacy, University of Nottingham. It has already been a test of resilience, learning about innovation, and begin to strategically thinking, in a different way from academic research, as you start to think how to venture outside of the academic lab. At this early stage, we recognise the importance of acknowledging both the milestones achieved and the challenges that have illuminated our path and new ways of learning and task to be achieved beyond the research its self.
Challenges as Stepping Stones
Our initial contact with the technology transfer office was a pivotal moment that set the wheels of innovation in motion. From the moment we took the first step towards securing patents, we found ourselves navigating through a labyrinth of intricacies. While the journey took longer than anticipated, it unveiled the complexity inherent in safeguarding our intellectual property. Each challenge encountered served as a stepping stone, enhancing our understanding of the meticulous groundwork required to ensure the future success of our endeavour. It is important for anyone thinking about technology transfer to emphasise early engagement and not disclose any information (avoid talking at conferences or with individuals outside unless you have a non-disclosure agreement, NDA).
\
Valuable Lessons in Patience and Adaptability and thinking about funding
The journey towards securing funding for our crucial in vivo study was a revelation into a lack of knowhow on my side. The successful acquisition of the MRC IIA (Impact accelerator) scheme grant marked a significant milestone, underscoring the validation of our vision. However, we quickly learned that the path from grant approval to study initiation is not without its own set of challenges. Negotiations between universities and the company required an unforeseen six-month timeline, teaching us the importance of patience and adaptability in the face of unforeseen delays. We will have a post doc visiting the lab in Italy to being the know how from the bioelectronics side of the project. The visa needed to achieve this both in the UK (as he is an International research fellow) and a joy of brexit that keeps on giving is now the complicated visa processes for Italy that we must do. All have contributed to delaying the start of this work.
De-risking by partnering
The strategic decision to conduct the pilot in vivo research in Italy over the UK underscored the agility required to overcome geographical constraints. The observation that disruption may not emanate from conservative pharmaceutical giants but rather from agile and visionary startups was a valuable insight. This was gained though open discussion with some of the world largest pharmaceutical companies.
Relationships have proved pivotal, exemplified by the interest of Israeli and UK companies rooted in personal connections and shared vision. The lesson that personal relationships can be the catalyst for investment underscored the importance of building strong connections within the industry.
Venture capitalists' advice to approach funding after completing the next study reinforced the need for meticulous planning and engagement with regulatory bodies such as the MRHA. The realisation of a slow-paced process emerged, along with the recognition that strategic engagement with therapeutic regulators is crucial for future success.
Moreover, whilst my group where engaged at the Asilomar Bioelectronics meeting in 2022 in conversation with venture capitalist they advised us to seek this further funding on requisition of the in vivo study. We plan on engaging with this in future, however, my priority would be the industrial partnership we have sort. However you should keep funding options open to de-risk.
Strategic Insights from Unforeseen Quarters:
Engaging with the technology transfer office offered insights that were crucial in shaping our strategic decisions. The decision to conduct our research in Italy, driven by the need for swifter progress, was a pivotal choice influenced by the invaluable guidance from this office. Through our interactions, we discovered the significance of agility and forward-thinking in overcoming geographical and bureaucratic hurdles.
Engaging with Ethical and Regulatory Aspects
Ethical approval, an essential checkpoint in our journey, revealed the importance of comprehensive preparation. The initial setback of an AWERB rejection due to our limited in vivo experience underscored the need for a meticulous approach. Learning from this experience, we are now in the process of resubmission, armed with a deeper understanding of the stringent requirements and the necessity for expert input.
Navigating the Regulatory Landscape
Another piece of advice is work with a clinician who is excited about the work and advocate for it and importantly offers insightful strategic directions to maximise chance of translation. After a meeting this week to discuss next steps in translation and reinforced the importance of engagement with regulatory bodies, such as the MRHA, in planning our upcoming studies. While the regulatory process might extend the timeline, it is a critical aspect that demands proactive involvement. The experience has led us to embrace the regulatory landscape as an integral part of our journey, shaping our strategic decisions and timelines.
Underscoring Conviction Amidst Challenges
Throughout this journey, one fundamental truth has remained unwavering: our profound belief in the revolutionary potential of quantum therapeutics. While challenges may arise and uncertainties may persist, our commitment to transforming cancer treatment endures. The road may be demanding, but the lessons learned thus far have fortified our determination to press forward, even when faced with the unexpected.
Collaborative Success Through Engagement
The engagement with the technology transfer office, from the project's outset, has proven to be a cornerstone of our progress. Their expertise, guidance, and proactive approach have proven invaluable in steering us through uncharted waters. We've learned that their support extends beyond paperwork—it encompasses strategic insights, regulatory navigation, and the encouragement needed to tackle challenges head-on. You have to work with none academic experts.
Conclusion: Challenges and solutions
Embarking on the uncharted journey to commercialise our revolutionary quantum therapeutic technology for hard-to-treat cancers has been an enlightening expedition. Thus far filled with challenges that have spurred innovation and strategic adaptation. From safeguarding intellectual property and securing funding to navigating ethical approvals and regulatory intricacies, each challenge has illuminated our path forward.
As we begin to try and venture beyond the confines of academic research, our experiences have highlighted the critical importance of early engagement with technology transfer offices, leveraging strategic partnerships, and embracing personal relationships to drive investment and collaboration. The wisdom gained from clinician insights and regulatory engagements has underscored the necessity of meticulous planning and proactive involvement to navigate the complex landscape of commercialisation.
Throughout this transformative journey, one resounding truth remains steadfast: our unwavering conviction in the transformative potential of quantum therapeutics. Despite uncertainties, delays, and unforeseen obstacles, our commitment to revolutionise cancer treatment through innovation burns brighter than ever. The support of the technology transfer office, extending beyond administrative roles to strategic guidance, has proven to be an invaluable asset.
As we stand at the intersection of scientific innovation and commercialisation, we carry forward the lessons learned, the partnerships forged, and the belief that our pioneering technology holds the key to reshaping the future of cancer treatment. The road ahead may be challenging, but armed with newfound insights and unwavering determination, we are poised to navigate this uncharted territory with resilience and optimism. Stay tuned for insights.
Comments